Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 7.6%

Protagonist Therapeutics Inc (NASDAQ:PTGX) shares rose 7.6% during mid-day trading on Thursday . The stock traded as high as $21.31 and last traded at $21.03. Approximately 480,576 shares traded hands during trading, a decline of 9% from the average daily volume of 528,374 shares. The stock had previously closed at $19.55.

PTGX has been the topic of several recent analyst reports. Jefferies Financial Group initiated coverage on Protagonist Therapeutics in a research note on Wednesday, July 15th. They set a “buy” rating and a $27.00 target price on the stock. Zacks Investment Research downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 13th. HC Wainwright lifted their price objective on Protagonist Therapeutics from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Finally, BidaskClub raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 25th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $27.42.

The stock has a market cap of $774.05 million, a PE ratio of -8.20 and a beta of 1.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.15 and a current ratio of 6.15. The stock has a fifty day moving average price of $20.28 and a 200 day moving average price of $14.64.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.02). The company had revenue of $6.22 million during the quarter, compared to analysts’ expectations of $3.80 million. Protagonist Therapeutics had a negative return on equity of 72.42% and a negative net margin of 438.96%. As a group, equities analysts anticipate that Protagonist Therapeutics Inc will post -2.55 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. boosted its holdings in Protagonist Therapeutics by 49.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,995 shares of the company’s stock valued at $35,000 after acquiring an additional 658 shares during the period. WINTON GROUP Ltd boosted its holdings in Protagonist Therapeutics by 2.2% during the 2nd quarter. WINTON GROUP Ltd now owns 38,611 shares of the company’s stock valued at $682,000 after acquiring an additional 828 shares during the period. Bank of Montreal Can boosted its holdings in Protagonist Therapeutics by 196.4% during the 2nd quarter. Bank of Montreal Can now owns 1,805 shares of the company’s stock valued at $32,000 after acquiring an additional 1,196 shares during the period. Citigroup Inc. lifted its holdings in shares of Protagonist Therapeutics by 24.5% in the 1st quarter. Citigroup Inc. now owns 7,022 shares of the company’s stock worth $50,000 after buying an additional 1,383 shares during the period. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth $35,000. Institutional investors own 93.09% of the company’s stock.

About Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Featured Story: Asset Allocation and Your Retirement

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.